Interactions Between Gut Microbiota and Acute Childhood Leukemia

Yuxi Wen, Runming Jin* and Hongbo Chen*

Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Childhood leukemia, the commonest childhood cancer, mainly consists of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Though great progresses have been made in the survival rates of childhood leukemia, the long-term health problems of long-term childhood leukemia survivors remain remarkable. In addition, the deep links between risk factors and childhood leukemia need to be elucidated. What can be done to improve the prevention and the prognosis of childhood leukemia is an essential issue. Gut microbiota, referred to as one of the largest symbiotic microorganisms that is accommodated in the gastrointestinal tract of human or animals, is found to be involved in the progression of various diseases. It is reported that microbiota may keep people in good health by participating in metabolism processes and regulating the immune system. Studies have also explored the potential relationships between gut microbiota and childhood leukemia. This review is meant to illustrate the roles of gut microbiota in the onset of acute childhood leukemia, as well as in the progress and prognosis of leukemia and how the treatments for leukemia affect gut microbiota. Besides, this review is focused on the possibility of building or rebuilding a healthy gut microbiota by adjusting the diet construction so as to help clinicians deal with childhood leukemia.

Keywords: gut microbiota, acute childhood leukemia, immune system, long-term health problem, diet construction

INTRODUCTION

Leukemia, the commonest childhood malignancy, mainly consists of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) (Stelianova-Foucher et al., 2017). Over the past decades, tremendous progresses have been made in the cure of childhood leukemia. The mortality rates of childhood cancers in the United States have decreased by more than 50% from 1975 to 2010, and the 5-year survival rate for ALL children <15 years old has increased to 91%, while the survival rate for AML children has increased to 68% (Smith et al., 2014). Genetic background, birth weight, birth order (Crump et al., 2015a,b; Paltiel et al., 2019), caesarean delivery (Marcotte et al., 2016), breastfeeding (Amitay and Keinan-Boker, 2015), low dose of ionizing radiation (Little et al., 2018), and some other exposures are reported to influence the incidence of childhood leukemia. However, the deep links between these factors and acute childhood leukemia lack exploration, and the exact mechanisms for acute childhood leukemia are still not clear.
Gut microbiota is recently recognized as a factor that could be important in regulating the progress of diseases (including gut diseases, diabetes, and others). Microbiota, microorganisms that accommodate at various sites of the human or animal body, develops during the first few years of life and then lives in symbiosis with humans all their life (Arrieta et al., 2014; Hollister et al., 2015; Cheng et al., 2016). Gut microbiota is considered to be one of the largest and most complex ecosystem that is coevolved with the gastrointestinal tract. Since several factors such as genetic, environmental, and lifestyle can influence microbial constitutions (Little et al., 2018; Rothschild et al., 2018), these factors along with gut microbiota should be evaluated as integrated for cancer progress. The aim of this review was to figure out current understandings on interactions between gut microbiota and acute childhood leukemia and make out what can be done in future studies for the management of childhood leukemia.

GUT MICROBIOTA CHANGES RAPIDLY DURING CHILDHOOD AND SHOULD BE TAKEN INTO ACCOUNT IN THE FUTURE STUDY DESIGN

With the development of gene sequencing methods, studies are able to be carried out to identify the constitution and diversity of microbiota as well as the crucial roles of microbiota in maintaining body health and regulating the progress of diseases. Several body sites (including the gastrointestinal tract, oral, skin, etc.) have been identified to harbor microbiota, among which the gastrointestinal tract is the largest and most complex one, which harbors approximately 100 trillion microorganisms (mainly composed of bacteria) in the human body (Bull and Plummer, 2014; Valdes et al., 2018). The roles of gut microbiota in maintaining body health have been explored (Beaumont et al., 2016; Falony et al., 2016; De Palma et al., 2017; Little et al., 2018), and gut microbiota is found to be vital for humans, probably by participating in metabolism, regulating the movement and development of the intestinal tract, promoting the development of the brain, as well as regulating the immune system (Zhang et al., 2015b; Levy et al., 2017; Chen et al., 2018; Rothschild et al., 2018; Valdes et al., 2018). With so many diseases discovered to be associated with gut microbiota, researchers are passionate about figuring out the roles of gut microbiota in various fields so as to find out something new for the clinical diagnosis and management of diseases.

Ever since birth, gut microbiota has interacted with the host’s conditions and shaped by numerous factors, such as genetic, diet construction, drugs, and others (Figure 1) (Little et al., 2018; Rothschild et al., 2018). Though the gut microbiome is divergent from people to people, the constitution and function of an individual’s gut microbiota remain relatively stable, which is quite important for maintaining health (Lozupone et al., 2012; Moya and Ferrer, 2016). Studies believed that gut microbiota is established at the first few years of life and keeps developing during the childhood until adulthood (Arrieta et al., 2014; Hollister et al., 2015; Cheng et al., 2016). A cohort study carried out among healthy preadolescent children with ages from 7 to 12 years found that the diversity of gut microbiota was at a similar level in healthy children and adults, while the composition and function of the microbiome differed. It mainly consists of Bifidobacterium spp. and Faecalibacterium spp. for children, while it mainly consists of Bacteroides spp. for adults. As for functional differences, most of the children’s microbiota are found to be able to promote development, while those of adults mostly participate in inflammation, obesity, etc. (Hollister et al., 2015). Another study that included children 1–4 years old drew similar results (Cheng et al., 2016). The gut microbiota community is found to change rapidly during the first few years and stay stable in the following years of adulthood until the decline of stability and function of the microbiota community for elders (Lan et al., 2013; Arrieta et al., 2014; Hollister et al., 2015; Cheng et al., 2016; An et al., 2018).

Differences in composition of the gut microbiota between healthy children and healthy adults, as well as the rapid change in childhood gut microbiota composition, stressed the importance of figuring out the specific vital leukemia-causing microorganisms based on a baseline childhood microbiota diversity and constitution. Arrieta et al. (2014) believed that the development of gut microbiota can be divided into six stages (at birth, 1 month, 6 month, 12 months, 3 years, and more than 3 years old) since the composition and diversity differed for every stage. For future studies on gut microbiota and childhood leukemia, the altering of gut microbiota along with aging should be taken into account. A recent study of gut microbiota, which involved 7,009 individuals from 14 districts in Guangdong province, showed that the locations of the hosts were associated with the variations of microbiota (He et al., 2018). Though there could be some confounding for this result, it reminds us that regional diversity is another factor which should be taken into account during the designing of future studies about microbiota.

STUDIES ABOUT THE POSSIBLE RELATIONSHIPS BETWEEN GUT MICROBIOTA AND LEUKEMIA

Since the incidence of ALL for children is much higher than that of AML (Steliarova-Foucher et al., 2017), studies for childhood AML are quite rare, and for better understanding, some studies about adult AML are included here. Nearly all children with leukemia are treated with systemic chemotherapy, and some may even receive allogeneic hematopoietic stem cell transplantation (allo-HSCT). Drugs used in chemotherapeutic and antibiotic treatments are known to disturb the host gut microbiota (Holler et al., 2014; Keeney et al., 2014) and, as a result, damage the mucosal protection and immunologic balance, and then contribute to the inflammation of the intestine (Holler et al., 2014).
WHICH SPECIFIC TYPES OF INFECTION ARE THE PROTECTIVE OR DETRIMENTAL FACTORS FOR THE OCCURRENCE OF CHILDHOOD LEUKEMIA

According to a landscape study, childhood cancers are frequently driven by a single disease-specific mutation, which is quite different from the mechanisms for adulthood cancers (Bandopadhayay and Meyerson, 2018). The most common alterations for pediatric leukemia are CDKN2A, IKZF1, ETV6, and RUNX1, which mainly participate in the regulation of cell cycle and transcription (Ma et al., 2018). Mutations in PAX1 (transcription) and NOTCH1 (notch) were only found in ALL, while mutations in CBFB (transcription) were only found in AML (Ma et al., 2018). For some subtypes of pediatric leukemia, the “two genetic hits” hypothesis proposes that a secondary genetic change is indispensable for the arisen on the basis of a fusion gene or hyperdiploidy ever since in the utero (Knudson, 2001; Greaves, 2018). It can be best verified by the decreasing concordance rate with aging for monochorionic twins. Although monochorionic twins are considered to share the same initial genetic change (with equal preleukemic stem cells), a secondary genetic change is believed to be the cause for the condition that only one of the twins develops ALL in children (Cazzaniga et al., 2011; Bateman et al., 2015) or AML in adults (Jaiswal et al., 2014; Shlush et al., 2014).

More than 20 possible exposures, such as prenatal factors (Marcotte et al., 2014; Crump et al., 2015a,b), caesarean delivery (Marcotte et al., 2016), breastfeeding (Amitay and Keinan-Boker, 2015), low dose of ionizing radiation (Little et al., 2018), as well as infections, have been reported to be related with the occurrence of acute childhood leukemia. The “delayed infection hypothesis” believed that earlier exposures to microbiome are protective factors for childhood ALL, while the later infections without earlier exposures may contribute to the vital secondary variation that causes leukemia (Greaves, 2018). Studies of factors that are associated with exposures to infections (such as birth order, timing of birth, and caesarean delivery by which children were not exposed to the microbes in the maternal vaginal) can support this hypothesis to a certain degree (Marcotte et al., 2016). The reduction of exposures to early common infections as well as factors that relate with microbiota colonization (such as breastfeeding, vaginal delivery) were considered to increase the risk of childhood leukemia (Ajrouche et al., 2015), while some other studies claimed that medically diagnosed infections in infancy or before diagnose of ALL or AML indicate increased risks for childhood leukemia (Chang et al., 2012; Rudant et al., 2015). As for the development of de novo adult AML, only gastrointestinal infections were considered to be risk factors (Ostgard et al., 2018).

The different conclusions of the different studies may come from the sample selection. By figuring out the earlier stage of infection and analyzing the relationship between acute childhood leukemia and earlier or later stage infections separately, conclusions might be more reliable. Studies stressed the fact that the immune system and microbial infectious exposures influence each other both in utero and in infancy (Olszak et al., 2012; Lim et al., 2015; Laforest-Lapointe and Arrieta, 2017; Torow and Hornef, 2017; Haas, 2018). However, how to define early-stage infections as well as how to prove the existence of it are still unsolved. Signe found that newborns who develop B-ALL later are characterized by abnormal concentrations of several inflammatory markers (Soegaard et al., 2018). The abnormal concentration of inflammatory markers represents an abnormal immune function at birth and reminds us that the immune function might play important roles in the development of acute childhood leukemia. The early childhood exposures to infection were associated with the proliferation and expansion of B or T cell clones (Olszak et al., 2012), and early common infections before the maturity of CD4 T cells are likely to adjust the constitution of symbiotic gut microbiota and contribute to an immune tolerance state toward some antigens with the aid of regulatory T cells and sIgA from mothers (Torow et al., 2015). The excessive reaction...
toward later-stage infection is likely to be the trigger of acute childhood leukemia. However, recent retrospective studies which rely on maternal recall are limited to figure out the existence of earlier-stage infections. Further researches are in great need to identify whether the earlier exposure to specific microorganisms reduces the incidence of childhood ALL, as well as childhood AML, by regulating the gut microbiota and thus contributing to the building of a healthy immune system.

INTERACTIONS BETWEEN GUT MICROBIOTA AND TREATMENTS FOR CHILDHOOD LEUKEMIA

Myelosuppression and immunosuppression are common conditions for children with leukemia during anticancer therapeutics. Infections (mostly bloodstream infections) that are followed by myelosuppression and immunosuppression play important roles in the morbidity and mortality for childhood leukemia. The disturbance of the gut microbiota during chemotherapy procedures and allo-HSCT in children with leukemia has been explored. Changes of stool microbiota were examined in a large cohort study of children with ALL to reflect the changes of gut microbiota. The diversity of fecal microbiota reduced remarkably after induction and reinduction chemotherapy (Hakim et al., 2018). Hakim et al. (2018) believed that the presentation of Proteobacteria including Enterobacteriaceae and Pseudomonas species, and other bacteria in the gut microbiome before or during chemotherapy could be used for predicting subsequent outcomes such as diarrhea, bloodstream infections, or febrile neutropenia for childhood leukemia. Similar conclusions have also drawn in some adult allo-HSCT, AML, and non-Hodgkin lymphoma (Montassier et al., 2015; Taur et al., 2015; Galloway-Pena et al., 2016). In the large cohort study, though the diversity of gut microbiota could recover to the initial level, the composition was different. The composition of the microbiota in children instead of the diversity in adults was identified to be independently predictive of infections caused by immunosuppression during chemotherapy (Hakim et al., 2018). Another study believed that the diversity and composition of gut microbiota before treatment can be applied to predict chemotherapy-related bloodstream infections (Montassier et al., 2016). However, a study proposes that stool microbiota is quite different from the microbiota that is detected from intestinal mucosa (Zmora et al., 2018). So, more studies are needed to confirm this opinion and to identify the representativeness of stool microbiota for gut microbiota.

Severely studies illustrated that the disturbance of microbiome caused by antibiotics is not always temporarly, but in some cases continues (Hernandez et al., 2013; Perez-Cobas et al., 2013; Vangay et al., 2015). Antibiotic-induced shifts can increase the susceptibility toward Clostridiodioides difficile infection (Hernandez et al., 2013). Methotrexate (MTX) is widely used in the treatment for childhood leukemia. Studies showed that the gastrointestinal toxic induced by MTX is vital for patient management (Paci et al., 2014). A mouse study showed that the disturbance of the gut microbiota for wild-type mice resulted in a tendency of suffering from MTX-induced mucosal injuries (Frank et al., 2015). A review claims that the microbiota interacts with anticancer drugs mainly in three aspects: improving the drug efficacy, reducing the anticancer effect, and increasing or reducing the toxicity (Panebianco et al., 2018).

The interactions between gut microbiota and therapeutic processes for childhood leukemia can be identified from divergent aspects: (1) whether the diversity and composition of gut microbiota can influence the efficacy or toxicity of drugs used during the therapeutic processes and how; (2) whether the treatments (chemotherapy or allo-HSCT) disturb the gut microbiota and how; (3) whether the gut microbiota can be used for predicting therapy-related complications (such as infections and diarrhea); and (4) whether it is possible for clinicians to deal with long-term health problems or therapy-related complications by regulating the gut microbiota.

WHAT CAN DIET REGULATION DO BOTH FOR GUT MICROBIOTA AND ACUTE CHILDHOOD LEUKEMIA

Since the balance of gut microbiota is rather important in childhood leukemia, efforts made to regulate or adjust the gut microbiota to a healthy state are in great need. Compared with administration of a multistrain probiotic preparation, the postantibiotic gut microbiota both in human and murine was rebuilt to the initial state more quickly by autologous fecal microbiome transplantation (Suez et al., 2018), similarly to three other researches (Yan et al., 2016; Bidu et al., 2018; Smillie et al., 2018; Suez et al., 2018). Besides, symbiosis between host and bacterium was believed to be dominantly driven by the bacterium’s adaptation to the host’s diet in a Drosophila model (Martino et al., 2018). Another study believed that melatonin (which is sufficient in several foods) supplementation can increase the diversity and regulate the composition of gut microbiota in mice (Ren et al., 2018). A meta-analysis that involved 18 studies believed that by breastfeeding for at least 6 months, the risks of childhood leukemia were reduced significantly compared with no or shorter-time breastfeeding (Amitay et al., 2016). There are sufficient probiotics and antibodies for specific pathogens (which each infant’s mother is exposed to) and much more natural killer cells in breast milk, which are essential for building a healthy microbiota in the gastrointestinal tract (Benno et al., 1984; Bode and Jantscher-Krenn, 2012; Brown, 2013). Thus, we can assume that the different outcomes of divergent diet constructions might come from the altered gut microbiota which evolved with the human immune system, especially for infants and children.

Long-term childhood leukemia survivors are faced with many long-term health problems such as obesity, cardiopulmonary toxicity, secondary malignancy, late neurotoxic effect, and others (Essig et al., 2014; Zhang et al., 2014; Cheung and Krull, 2015; Withycombe et al., 2015; Duncan et al., 2018). The unhealthy dietary behaviors (such as high intake of fat, sodium, sweets, and low intake of fruit, vegetables, and whole
grains) (Tylavsky et al., 2010; Badr et al., 2011; Fuenmeler et al., 2013; Zhang et al., 2015a; Duncan et al., 2018) of childhood cancer survivors and the usage of antibiotics are known to increase weight by regulating the composition of the gut microbiota (Blaser, 2016). Obesity was identified to be a risk for childhood leukemia, while fasting was found to reduce the incidence and even reverse the progression of ALL in mouse models (Orgel et al., 2016; Lu et al., 2017). Hopefully, the incidence and progression of leukemia are likely to be stopped or reversed by simply fasting; prolonging the duration of breastfeeding; adjusting to a low intake of fat, sodium, and sweets; and a high intake of fruit, vegetables, and whole grains. Besides, whether the supplement of melatonin or probiotics, as well as fecal microbiome transplantation, can help keep a healthy gut microbiota in children with leukemia remains to be explored.

CONCLUSIONS

Recent studies have explored the possible relationships between gut microbiota and acute childhood leukemia. The “delayed infection hypothesis” highlights a favorable role of early infection in preventing the onset of childhood leukemia. This is somehow consistent with the idea that an oversanitized condition may lead to some noninfectious and immunological diseases like asthma, obesity, and diabetes. It is also found that gut microbiota develops with ageing. However, which specific microorganisms help push the onset and progression of childhood leukemia is still unclear. Besides, diet regulation such as fasting and breastfeeding may lower the incidence of childhood leukemia and reverse the progression by adjusting the gut microbiota. All of the above implies that acute childhood leukemia may be somewhat preventable by changing the lifestyle. In turn, antileukemia therapies can disturb the gut microbiota and bring short- and long-term health problems. This may be addressed in the future by gut microbiota transplantation and probiotic supplements, which demands some prospective studies in leukemia patients first.

There is also an urgent need to figure out the specific microorganisms for the onset and progression of childhood leukemia and dig out the latent mechanisms for the links between gut microbiota and childhood leukemia. By doing so, more targeted therapy (such as specific probiotic supplements, specific microbiome transplantation, as well as diet regulation that benefits specific microorganisms) instead of nontargeted probiotic supplements or others for reducing the incidence of leukemia and eliminating antileukemia treatment-related long-term health problems could be put forward. As for study design, both regions and ages should be taken into account to generate a confident baseline childhood microbiome diversity and constitution. In addition, the representativeness of stool microbiota for gut microbiota is in doubt and needs further confirmation.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

This work was supported by a grant from National Natural Science Foundation of China (31701207 to HC).

REFERENCES

Ajrouche, R., Rudant, J., Orsi, L., Petit, A., Baruchel, A., Lambilliotte, A., et al. (2015). Childhood acute lymphoblastic leukaemia and indicators of early immune stimulation: the Estelle study (SFCE). Br. J. Cancer 112, 1017–1026. doi: 10.1038/bjc.2015.53

Amitay, E. L., Dubnov Raz, G., and Keinan-Boker, L. (2016). Breastfeeding, other early life exposures and childhood leukemia and lymphoma. Nutr. Cancer. 68, 968–977. doi: 10.1080/01635581.2016.1190020

Amitay, E. L., and Keinan-Boker, L. (2015). Breastfeeding and childhood leukemia incidence: a meta-analysis and systematic review. JAMA Pediatr. 169:e151025. doi: 10.1001/jamapediatrics.2015.1025

An, R., Wilms, E., Masclaux, A. A. M., Smidt, H., Zoetendal, E. G., and Jonkers, D. (2018). Age-dependent changes in GI physiology and microbiota: time to reconsider? Gut 67, 2213–2222. doi: 10.1136/gutjnl-2017-315542

Arrieta, M. C., Stiemsma, L. T., Amenyogbe, N., Brown, E. M., and Finlay, B. (2014). The intestinal microbiome in early life: health and disease. Front. Immunol. 5:427. doi: 10.3389/fimmu.2014.00427

Beaumont, M., Goodrich, J. K., Jackson, M. A., Yet, I., Davenport, E. R., Vieira-Silva, S., et al. (2016). Heritable components of the human fecal microbiome are associated with visceral fat. Genome Biol. 17:189. doi: 10.1186/s13059-016-1052-7

Benno, Y., Sawada, K., and Mitsuoka, T. (1984). The intestinal microflora of infants: composition of fecal flora in breast-fed and bottle-fed infants. Microbiol. Immunol. 28, 975–986. doi: 10.1111/j.1348-0421.1984.tb0754.x

Bidi, C., Escoula, Q., Bellenger, S., Spor, A., Galan, M., Geissler, A., et al. (2018). The transplantation of omega3 PUFA-altered gut microbiota of fat-1 mice to wild-type littersmates prevents obesity and associated metabolic disorders. Diabetes 67, 1512–1523. doi: 10.2337/db17-1488

Blaser, M. J. (2016). Antibiotic use and its consequences for the normal microbiome. Science 352, 544–545. doi: 10.1126/science.aad9358

Bode, L., and Jantscher-Krenn, E. (2012). Structure–function relationships of human milk oligosaccharides. Adv. Nutr. 3, 383s–391s. doi: 10.3945/an.111.001404

Brown, P. (2013). Treatment of infant leukemias: challenge and promise. Hematology Am. Soc. Hematol. Educ. Program 2013, 596–600. doi: 10.1182/asheducation-2013.1.596

Bull, M. J., and Plummer, N. T. (2014). Part 1: the human gut microbiome in health and disease. Int. Med. 13, 17–22.

Cazzaniga, G., van Delft, F. W., Lo Nigro, L., Ford, A. M., Score, J., Iacobucci, I., et al. (2011). Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. Blood 118, 5559–5564. doi: 10.1182/blood-2011-07-365452

Chang, J. S., Tsai, C. R., Tsai, Y. W., and Wiemels, J. L. (2012). Medically diagnosed infections and risk of childhood leukemia: a population-based case-control study. Int. J. Epidemiol. 41, 1050–1059. doi: 10.1093/ije/dys113
Chen, G., Huang, B., Fu, S., Li, B., Ran, X., He, D., et al. (2018). G protein-coupled receptor 109A and host microbiota modulate intestinal epithelial integrity during sepsis. *Front. Immunol.*, 9:2079. doi: 10.3389/fimmu.2018.02079

Cheng, J., Ringel-Kulka, T., Heiskamp-de Jong, I., Ringel, Y., Carroll, L., de Vos, W. M., et al. (2016). Dissecting the temporal development of bacterial phyla and the emergence of core in the fecal microbiota of young children. *ISME J.*, 10, 1002–1014. doi: 10.1038/ismej.2015.177

Cheung, Y. T., and Krull, K. R. (2015). Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: a systematic review. *Neurosci. Biobehav. Rev.*, 53, 108–120. doi: 10.1016/j.neubiorev.2015.03.016

Crump, C., Sundquist, J., Sieh, W., Winkleby, M. A., and Sundquist, K. (2015a). Perinatal and familial risk factors for acute lymphoblastic leukemia in a Swedish national cohort. *Cancer*, 121, 1040–1047. doi: 10.1002/cncr.29172

Crump, C., Sundquist, J., Sieh, W., Winkleby, M. A., and Sundquist, K. (2015b). Perinatal risk factors for acute myeloid leukemia. *Eur. J. Epidemiol.*, 30, 1277–1285. doi: 10.1007/s10654-015-0063-0

De Palma, G., Lynch, M. D., Lu, J., Dang, V. T., Deng, Y., Jury, J., et al. (2017). Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. *Sci. Transl. Med.*, 9 eaaf6397. doi: 10.1126/scitransmed.aaf6397

Duncan, C. N., Brazauskas, R., Huang, J., Shaw, B. E., Majhail, N. S., Savani, B. N., et al. (2018). Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.*, 53, 1278–1288. doi: 10.1038/s41409-018-0106-y

Essig, S., Li, Q., Chen, Y., Hitzler, J., Leisenring, W., Greenberg, M., et al. (2014). Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. *Lancet Oncol.*, 15, 841–851. doi: 10.1016/S1470-2045(14)70265-7

Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., et al. (2016). Population-level analysis of gut microbiome variation. *Science*, 352, 560–564. doi: 10.1126/science.aad3503

Frank, M., Hennenberg, E. M., Eying, A., Runzi, M., Gerken, G., Scott, P., et al. (2015). TLR signaling modulates side effects of anticaner therapy in the small intestine. *J. Immunol.*, 194, 1983–1995. doi: 10.4049/jimmunol.1402481

Fuemmler, B. F., Penzich, M. K., Clark, K., Lovelady, C., Rosoff, P., Blatt, J., Frank, M., Hennenberg, E. M., Eyking, A., Runzi, M., Gerken, G., Scott, P., et al. (2016). Discordant temporal development of bacterial and fungal microbiota and host immune system. *ISME J.*, 10, 2198–2208. doi: 10.1038/ismej.2015.177

Hernandez, E., Bargiela, R., Diez, M. S., Friedrichs, A., Perez-Cobas, A. E., Haas, O. A. (2018). Functional consequences of microbial shifts to low doses (< 100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies. *Lancet Haematol.*, 5, e346–e358. doi: 10.1016/S2353-3026(18)30092-9

Lan, Y., Kriete, A., and Rosen, G. L. (2013). Selecting age-related functional characteristics in the human gut microbiome. *Microbiome* 1:2. doi: 10.1016/j.bbmt.2014.01.030

Levy, M., Kolodziejczyk, A. A., Thaiss, C. A., and Elinav, E. (2017). Dysbiosis and the immune system. *Nat. Rev. Immunol.*, 17, 219–232. doi: 10.1038/ nrit.2017.7

Lim, E. S., Zhou, Y., Zhao, G., Bauer, I. K., Droit, L., Ndao, I. M., et al. (2015). Early life dynamics of the human gut virome and bacterial microbiome in infants. *Nat. Med.*, 21, 1228–1234. doi: 10.1038/nm3950

Little, M. P., Wakeford, R., Borrego, D., French, B., Zablotska, L. B., Adams, M. J., et al. (2018). Leukaemia and myeloid malignancy among people exposed to low doses (< 100 mSv) of ionising radiation during childhood: a pooled analysis of nine cohort studies. *Lancet Haematol.*, 5, e346–e358. doi: 10.1016/S2353-3026(18)30092-9

Lopozune, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., and Knight, R. (2012). Diversity, stability and resilience of the human gut microbiota. *Nature* 489, 220–230. doi: 10.1038/nature11550

Lu, Z., Xie, J., Wu, G., Shen, J., Collins, R., Chen, W., et al. (2017). Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. *Nat. Med.*, 23, 79–90. doi: 10.1038/nm.4252

Ma, X., Liu, Y., Liu, Y., Alexandrov, L. B., Edmonson, M. N., Gawad, C., et al. (2018). Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. *Nature* 555, 371–376. doi: 10.1038/nature25795

Marcotte, E. L., Ritz, B., Cockburn, M., Yu, F., and Heck, J. E. (2014). Exposure to infections and risk of leukemia in young children. *Cancer Epidemiol. Biomarkers Prev.*, 23, 1195–1203. doi: 10.1158/1055-9966.epi-13-1330

Marcotte, E. L., Thomopoulos, T. P., Infante-Rivard, C., Clavel, J., Petridou, E. T., Schuz, J., et al. (2016). Caesarean delivery and risk of childhood leukaemia: a pooled analysis from the Childhood Leukaemia International Consortium (CLIC). *Lancet Haematol.*, 3, e165–e168. doi: 10.1016/S2352-3026(16)00002-8

Martino, M. E., Joncour, P., Leenay, R., Gervas, H., Shah, M., Hughes, S., et al. (2018). Bacterial adaptation to the host's diet is a key evolutionary force shaping Drosophila–Lactobacillus symbiosis. *Cell Host Microbe*, 24, 109–119.e106. doi: 10.1016/j.chom.2018.06.001

Montassier, E., Al-Ghali, G. A., Ward, T., Corvec, S., Gastinne, T., Potel, G., et al. (2016). Pretreatment gut microbiota predicts chemotherapy-related bloodstream infection. *Genome Med.* 8:49. doi: 10.1186/s13073-016-0310-4

Montassier, E., Gastinne, T., Vangay, P., Al-Ghalith, G. A., Bruley des Varannes, S., Massart, S., et al. (2015). Chemotherapy-driven dysbiosis in the intestinal microbiome. *Cell Host Microbe*, 18, 471–484. doi: 10.1016/j.chom.2018.06.001

Olszak, T., An, D., Zeissig, S., Vera, M. P., Richter, J., Franke, A., et al. (2012). Primary immunodeficiency and the immune system. *Nat. Rev. Immunol.*, 17, 219–232. doi: 10.1038/nri.2012.249

Pavic M., Vlahov D., and Fink G. (2014). Review of therapeutic drug monitoring of anticancer drugs part 1—cytotoxics. *Eur. J. Cancer* 50, 2010–2019. doi: 10.1016/j.ejca.2014.04.014
Paltiel, O., Lemeshow, S., Phillips, G. S., Tikellis, G., Linet, M. S., Ponsonby, A. L., et al. (2019). The association between birth order and childhood leukemia may be modified by paternal age and birth weight. Pooled results from the International Childhood Cancer Cohort Consortium (4IC). Int. J. Cancer 144, 26–33. doi: 10.1002/ijc.31635

Panbioncino, C., Andriulli, A., and Pazienza, V. (2018). Pharmacomicobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 6:92. doi: 10.1186/s40168-018-0483-7

Perez-Cobas, A. E., Artacho, A., Knecht, H., Ferrus, M. L., Friedrichs, A., Ott, S. J., et al. (2013). Differential effects of antibiotic therapy on the structure and function of human gut microbiota. PLoS One 8:e80201. doi: 10.1371/journal.pone.0080201

Ren, W., Wang, P., Yan, J., Liu, G., Zeng, B., Hussain, T., et al. (2018). Melatonin alleviates weanling stress in mice: involvement of intestinal microbiota. J. Pineal Res. 64:e12448. doi: 10.1111/jpi.12448

Rothschild, D., Weisbrod, O., Barkan, E., Kurilshikov, A., Koren, T., Zeevi, D., et al. (2018). Environment dominates over host genetics in shaping human gut microbiota. Nature 555, 210–215. doi: 10.1038/nature25973

Rudant, J., Lightfoot, T., Urarayka, K. Y., Petridou, E., Dockerty, J. D., Magnani, C., et al. (2015). Childhood acute lymphoblastic leukemia and indicators of early immune stimulation: a Childhood Leukemia International Consortium study. Am. J. Epidemiol. 181, 549–562. doi: 10.1093/aje/kuv298

Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., et al. (2014). Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 326–333. doi: 10.1038/nature13038

Smillie, C. S., Sauk, J., Gevers, D., Friedman, J., Sung, J., Youngster, I., et al. (2018). Strain tracking reveals the determinants of bacterial engrafment in the human gut following fecal microbiota transplantation. Cell Host Microbe 23, 229–240.e225. doi: 10.1016/j.chom.2018.04.006

Smith, M. A., Altekruse, S. F., Adamson, P. C., Reaman, G. H., and Seibel, N. L. (2014). Declining childhood and adolescent cancer mortality. Cancer 120, 2497–2506. doi: 10.1002/cncr.28748

Soegaard, S. H., Rostgaard, K., Skogstrand, K., Wiemels, J. L., Schmiegelow, K., and Hjalgrim, H. (2018). Neonatal inflammatory markers are associated with childhood B-cell precursor acute lymphoblastic leukemia. Cancer Res. 78, 5458–5463. doi: 10.1158/0008-5472.CAN-18-0831

Stilarova-Foucher, E., Colombet, M., Ries, L. A. G., Moreno, F., Dolya, A., Bray, F., et al. (2017). International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 18, 719–731. doi: 10.1016/S1470-2045(17)30186-9

Suez, J., Zmora, N., Zilberman-Schapira, G., Mor, U., Dori-Bachash, M., Bashirades, S., et al. (2018). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell 174, 1406–1423.e1416. doi: 10.1016/j.cell.2018.08.047

Taur, Y., Jeng, R. R., Ubeda, C., van den Brink, M., and Pamer, E. G. (2015). Role of intestinal microbiota in transplantation outcomes. Best Pract. Res. Clin. Haematol. 28, 155–161. doi: 10.1016/j.beha.2015.10.013

Torow, N., and Hornef, M. W. (2017). The neonatal window of opportunity: setting the stage for life-long host-microbial interaction and immune homeostasis. J. Immunol. 198, 557–563. doi: 10.4049/jimmunol.1601253

Torow, N., Yu, K., Hassani, K., Freitag, J., Schulz, O., Basic, M., et al. (2015). Active suppression of intestinal CD4(+)TCRalphabeta(+) T-lymphocyte maturation during the postnatal period. Nat. Commun. 6:7725. doi: 10.1038/ncomms8725

Tylavsky, F. A., Smith, K., Surpise, H., Garland, S., Yan, X., McCammon, E., et al. (2010). Nutritional intake of long-term survivors of childhood acute lymphoblastic leukemia: evidence for bone health interventional opportunities. Pediatr. Blood Cancer 55, 1362–1369. doi: 10.1002/pbc.22737

Valdes, A. M., Walter, J., Segal, E., and Spector, T. D. (2018). Role of the gut microbiota in nutrition and health. BMJ 361:k2179. doi: 10.1136/bmj.k2179

Vangay, P., Ward, T., Gerber, J. S., and Knights, D. (2015). Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe 17, 553–564. doi: 10.1016/j.chom.2015.04.006

Withycombe, J. S., Smith, L. M., Meza, J. L., Merkle, C., Faulkner, M. S., Ritter, L., et al. (2015). Weight change during childhood acute lymphoblastic leukemia induction therapy predicts obesity: a report from the Children's Oncology Group. Pediatr. Blood Cancer 62, 434–439. doi: 10.1002/pbc.25316

Yan, H., Diao, H., Xiao, Y., Li, W., Yu, B., He, J., et al. (2016). Gut microbiota can transfer fiber characteristics and lipid metabolic profiles of skeletal muscle from pigs to germ-free mice. Sci. Rep. 6:31786. doi: 10.1038/srep31786

Zhang, F. F., Rodday, A. M., Kelly, M. J., Must, A., MacPherson, C., Roberts, S. B., et al. (2014). Predictors of being overweight or obese in survivors of pediatric acute lymphoblastic leukemia (ALL). Pediatr. Blood Cancer 61, 1263–1269. doi: 10.1002/pbc.24960

Zhang, F. F., Saltzman, E., Kelly, M. J., Liu, S., Must, A., Parsons, S. K., et al. (2015a). Comparison of childhood cancer survivors’ nutritional intake with US dietary guidelines. Pediatr. Blood Cancer 62, 1461–1467. doi: 10.1002/pbc.25521

Zhang, H., Sparks, J. B., Karyala, S. V., Settlage, R., and Luo, X. M. (2015b). Host adaptive immunity alters gut microbiota. ISME J. 9, 770–781. doi: 10.1038/ismej.2014.165

Zmora, N., Zilberman-Schapira, G., Suez, J., Mor, U., Dori-Bachash, M., Bashirades, S., et al. (2018). Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 174, 1388–1405.e1321. doi: 10.1016/j.cell.2018.08.041

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Wen, Jin and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.